Why the study?
TAVR in severe aortic stenosis with raphe-type bicuspid aortic valve has poor outcomes and lacks consensus on the optimal sizing method for prosthesis selection.
Does TAVR with the Evolut FX prosthesis sized using the LIRA method achieve high 30-day device success in patients with severe aortic stenosis and raphe-type bicuspid aortic valve?
Does TAVR with the Evolut FX prosthesis sized using the LIRA method achieve high 30-day device success in patients with severe aortic stenosis and raphe-type bicuspid aortic valve?
In this initial case series of 5 patients with raphe-type bicuspid aortic valve stenosis, combining the supra-annular LIRA sizing method with the Evolut FX TAVR prosthesis resulted in 100% 30-day device and technical success with stable deployment and no stroke, mortality, or moderate/severe paravalvular leak.
Answers are grounded in this paper and cite their sources.
Should not yet change TAVR practice in raphe-type BAV; hypothesis-generating for LIRA-Evolut FX combination.
Transcatheter aortic valve replacement (TAVR) in patients with severe aortic stenosis and raphe-type bicuspid aortic valve (BAV) is still associated with poor outcomes in terms of increased risk of paravalvular regurgitation, stroke, and permanent pacemaker implantation. There is no definitive consensus on the optimal sizing method for prosthesis selection in this setting. The LIRA method is a supra-annular tailored sizing method specifically designed for bicuspid anatomy that might increase accuracy of prosthesis choice in BAV patients and improve TAVR outcomes. This is the first report of the combination of the novel LIRA method for prosthesis sizing together with the adoption of the technological improvements introduced by the Evolut FX prosthesis as a useful tool for improving outcomes in this high risk subgroup of patients.
No takes yet. Share an insight, caveat, or question.
Napoli et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: